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Association of noncirrhotic portal hypertension in HIV-infected
persons and antiretroviral therapy with didanosine: a nested
case-control study
Abstract
BACKGROUND: Noncirrhotic portal hypertension (NCPH) is a newly described life-threatening liver
disease of unknown cause in human immunodeficiency virus (HIV)-infected persons. Postulated
pathogenesis includes prolonged exposure to antiretroviral therapy, particularly didanosine.
METHODS: We performed a nested case-control study including 15 patients with NCPH and 75
matched control subjects of the Swiss HIV Cohort Study to investigate risk factors for the development
of NCPH. Matching criteria were similar duration of HIV infection, absence of viral hepatitis, and
follow-up to at least the date of NCPH diagnosis in the respective case. RESULTS: All 15 case patients
had endoscopically documented esophageal varices and absence of liver cirrhosis on biopsies; 4 died
because of hepatic complications. At NCPH diagnosis, case patients and control subjects were similar
concerning sex; race; Centers for Disease Control and Prevention stage; HIV-RNA level; CD4 cell
count nadir; and lipids and lipodystrophy. Differences were found in age (conditional logistic regression
odds ratio [OR] for 10 years older, 2.9; 95% confidence interval [CI], 1.4-6.1); homosexuality (OR, 4.5;
95% CI, 1.2-17); current CD4 cell count <200 cells/microL (OR, 34.3; 95% CI, 4.3-277); diabetes
mellitus (OR, 8.8; 95% CI, 1.6-49); alanine aminotransferase level higher than normal (OR, 13.0; 95%
CI, 2.7-63); alkaline phosphatase higher than normal (OR, 18.3; 95% CI, 4.0-85); and platelets lower
than normal (OR, 20.5; 95% CI, 2.4-178). Cumulative exposure to antiretroviral therapy (OR per year,
1.3; 95% CI, 1.0-1.6), nucleoside reverse-transcriptase inhibitor (OR, 1.3; 95% CI, 1.1-1.7), didanosine
(OR, 3.4; 95% CI, 1.5-8.1), ritonavir (OR, 1.4; 95% CI, 1.0-1.9), and nelfinavir (OR, 1.4; 95% CI,
1.0-1.9) were longer in case patients. Exposure to nonnucleoside reverse-transcriptase inhibitor and
other protease inhibitors were not different between groups. In bivariable models, only the association of
NCPH with didanosine exposure was robust; other covariables were not independent risk factors.
CONCLUSIONS: We found a strong association between prolonged exposure to didanosine and the
development of NCPH.
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Association of Noncirrhotic Portal Hypertension
in HIV-Infected Persons and Antiretroviral Therapy
with Didanosine: A Nested Case-Control Study
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Background. Noncirrhotic portal hypertension (NCPH) is a newly described life-threatening liver disease of
unknown cause in human immunodeficiency virus (HIV)–infected persons. Postulated pathogenesis includes
prolonged exposure to antiretroviral therapy, particularly didanosine.
Methods. We performed a nested case-control study including 15 patients with NCPH and 75 matched control
subjects of the Swiss HIV Cohort Study to investigate risk factors for the development of NCPH. Matching criteria
were similar duration of HIV infection, absence of viral hepatitis, and follow-up to at least the date of NCPH
diagnosis in the respective case.
Results. All 15 case patients had endoscopically documented esophageal varices and absence of liver cirrhosis
on biopsies; 4 died because of hepatic complications. At NCPH diagnosis, case patients and control subjects were
similar concerning sex; race; Centers for Disease Control and Prevention stage; HIV-RNA level; CD4 cell count
nadir; and lipids and lipodystrophy. Differences were found in age (conditional logistic regression odds ratio [OR]
for 10 years older, 2.9; 95% confidence interval [CI], 1.4–6.1); homosexuality (OR, 4.5; 95% CI, 1.2–17); current
CD4 cell count !200 cells/mL (OR, 34.3; 95% CI, 4.3–277); diabetes mellitus (OR, 8.8; 95% CI, 1.6–49); alanine
aminotransferase level higher than normal (OR, 13.0; 95% CI, 2.7–63); alkaline phosphatase higher than normal
(OR, 18.3; 95% CI, 4.0–85); and platelets lower than normal (OR, 20.5; 95% CI, 2.4–178). Cumulative exposure
to antiretroviral therapy (OR per year, 1.3; 95% CI, 1.0–1.6), nucleoside reverse-transcriptase inhibitor (OR, 1.3;
95% CI, 1.1–1.7), didanosine (OR, 3.4; 95% CI, 1.5–8.1), ritonavir (OR, 1.4; 95% CI, 1.0–1.9), and nelfinavir
(OR, 1.4; 95% CI, 1.0–1.9) were longer in case patients. Exposure to nonnucleoside reverse-transcriptase inhibitor
and other protease inhibitors were not different between groups. In bivariable models, only the association of
NCPH with didanosine exposure was robust; other covariables were not independent risk factors.
Conclusions. We found a strong association between prolonged exposure to didanosine and the development
of NCPH.
Mortality and morbidity from AIDS-defining diseases
has decreased dramatically since the introduction of
combination antiretroviral therapy (ART) [1, 2]. As
persons infected with human immunodeficiency virus
(HIV) live longer, serious non–AIDS-defining diseases
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become increasingly important, and novel clinical man-
ifestations or disease entities may emerge. Liver-related
morbidity and mortality are major problems among
HIV-infected patients [3]. Main causes of chronic liver
disease are infection due to hepatitis C virus and hep-
atitis B virus, alcohol abuse, nonalcoholic fatty liver
disease, and drug-induced toxicity [4]. Prolonged ex-
posure to some antiretroviral drugs might increase he-
patic mortality [3].
Recently, several reports of HIV-infected persons
with symptomatic noncirrhotic portal hypertension
(NCPH) were published [5–13] (table 1). Patients pre-
sented with esophageal varices, variceal bleeding, as-
cites, splenomegaly, and rarely, encephalopathy. In
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many cases, portal thrombosis was noted. Some patients de-
veloped severe complications that required liver transplanta-
tion. Liver biopsies revealed no cirrhosis, and in a great part,
nodular regenerative hyperplasia was found. Histological
changes were usually very subtle and often were not detected
using routine stains. The etiology of this new disease in HIV-
infected patients remains obscure. Besides a prothrombotic
state and HIV itself, ART, particularly didanosine (DDI), has
been postulated as a cause. However, implicating which med-
ication might cause NCPH in ART-experienced patients is dif-
ficult, because patients usually have an ART history with nu-
merous different drugs.
The methodology of those reports, however, does not allow
for clear-cut conclusions on the association of NCPH with the
use of antiretrovirals. Besides 2 case reports and 6 case series,
only 1 case-control study was published (table 1). That case-
control study assessed HIV-infected patients with elevated liver
enzymes of unknown origin; only a subset of case patients (9
of 17 case patients) had portal hypertension. Liver biopsy was
performed in 5 patients, of whom 2 had cirrhosis [5–13]. In
the Swiss HIV Cohort Study, we have encountered a number
of patients with unexplained NCPH. The purpose of this study
was to identify risk factors for this newly described disease by
means of a nested case-control design and strict criteria for the
diagnosis of NCPH.
METHODS
Study population. The Swiss HIV Cohort Study is an on-
going, prospective cohort study that was established in 1988
and that continually enrolls and observes HIV-infected indi-
viduals aged16 years at 5 university outpatient clinics, 2 large
district hospitals, affiliated regional hospitals, and private prac-
tices [14]. Information and laboratory values are collected in
accordance with defined criteria at registration and at follow-
up visits every 6 months. The study was approved by local
ethical review boards, and written informed consent was ob-
tained from all participants.
Patients with idiopathic NCPH were retrospectively identi-
fied by patient charts. A review of medical charts of all case
patients was performed, and data were extracted using a stan-
dardized data-collection form. Inclusion criteria were the pres-
ence of endoscopically documented esophageal varices or he-
patic venous pressure gradient10 mm Hg, absence of hepatic
cirrhosis on liver biopsy, and no common cause of liver disease,
such as hepatitis C virus or active hepatitis B virus infection,
elevated alcohol consumption, hemochromatosis, Wilson dis-
ease, a1-antitrypsin deficiency, autoimmune hepatitis, nonal-
coholic fatty liver disease, and hepatotoxic drugs. Hepatitis C
virus infection was defined as present in patients who were
seropositive for hepatitis C virus or who had test results positive
for hepatitis C virus RNA. Active hepatitis B virus infection
was defined as present in patients who were seropositive for
hepatitis B surface antigen or hepatitis B e antigen or who had
detectable hepatitis B virus DNA. Time of diagnosis of portal
hypertension was defined by the time of confirmation of esoph-
ageal varices. For patients without a known date of serocon-
version, we assessed the date of HIV infection in accordance
with a back calculation model [15].
For each case patient, we selected 5 control subjects from
the Swiss HIV Cohort Study without viral hepatitis, with a
similar date of HIV infection (6 months), and with a follow-
up to at least the date of diagnosis of NCPH in the corre-
sponding case patient.
Statistical analysis. Associations between NCPH and the
following factors were assessed by univariable and bivariable
conditional logistic regression: demographic characteristics
(age, sex, mode of HIV acquisition, and race); presence of
diabetes mellitus; current values for body mass index, blood
pressure, lipodystrophy, total and high-density lipoprotein cho-
lesterol, triglycerides, alanine aminotransferase, and alkaline
phosphatase; current and nadir CD4 cell count; current and
maximum HIV-1 viral load; previous clinical AIDS events; and
exposure to different drug classes, different nucleoside reverse-
transcriptase inhibitor (NRTI) backbone-combinations, and in-
dividual antiretroviral drugs. Central obesity was defined in
accordance with the new worldwide definition [16], with sex-
and ethnicity-specific waist circumference cut-off values as fol-
lows: Europeans and sub-Saharan Africans, 94 cm for males
and 80 cm for females; south Asians, Chinese, and south and
central Americans, 90 cm for males and80 cm for females;
and Japanese, 85 cm for males and 90 cm for females. A
full multivariable model was not possible because of the limited
number of case patients. Variables with significant associations
in the univariable analysis were used as covariables in bivariable
models together with DDI exposure per year. We considered
only cumulative drug exposure for univariable and bivariable
models because of potential reverse causality problems with
current use. A Kaplan-Meier survival analysis of matched HIV-
infected control subjects and patients with NCPH was made.
For statistical analysis, we used Stata software, version 10.1
(StataCorp).
RESULTS
Description of case patients. From September 2000 through
May 2007, we observed 15 patients with unexplained NCPH.
First symptoms that prompted investigations of the portal sys-
tem were elevated liver enzymes, hematemesis, or ascites. The
majority were male (13 [87%]) and had acquired HIV through
homosexual intercourse (11 [73%]). The median age at time
of diagnosis was 52 years (interquartile range [IQR], 47–59
years). All 15 case patients were ART experienced. At time of
diagnosis, 11 (73%) were receiving ART and 4 (27%) had in-
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terrupted ART because of suspected hepatotoxicity. In 9 case
patients (60%), viral load was undetectable; in another 2, viral
load was !100 copies/mL. Mean time from diagnosis of HIV
to diagnosis of NCPH was 14.6 years (IQR, 10.8–18.2 years).
All 15 case patients had endoscopically documented esophageal
varices; 7 developed recurrent episodes of variceal bleeding.
Thirteen case patients were found to have splenomegaly (in 2,
the size of the spleen was not documented). Ascites was re-
corded in 8 case patients and hepatic encephalopathy in 2. At
time of diagnosis, portal vein thrombosis was present in 3 case
patients; during follow-up, it was present in 2. Alkaline phos-
phatase and liver enzymes were mostly only mildly and inter-
mittently elevated. Markers for liver synthesis were usually nor-
mal, and platelets were often slightly less than the normal limit.
At least 1 liver biopsy, either transabdominal or transjugular,
was performed in all patients. None of the liver biopsies showed
cirrhosis. Histology did reveal a variety of lesions often occur-
ring together, such as periportal fibrosis in 10 case patients
(67%), perisinusoidal fibrosis in 1 (7%), sinusoidal dilatation
in 1 (7%), low grade portal and lobular inflammation in 7
(47%), ductopenia and ductular proliferation in 4 (27%), mac-
rovacuolar and/or microvesicular steatosis in 6 (40%), and he-
patocellular necrosis in 4 (27%). Nodular regenerative hyper-
plasia was seen in the biopsy of one patient (7%) and normal
liver appearance in the biopsy of another one (7%).
Treatment was symptomatic following the same protocol as
in cirrhosis, including b-blocker, variceal banding, and diuret-
ics. One patient was treated with transjugular intrahepatic por-
tal systemic shunting for refractory symptoms; no one received
a liver transplant.
Comparison of demographic and clinical characteristics of
case patients and control subjects. The comparison of 15 case
patients and 75 control subjects as well as the results of uni-
variable conditional logistic regression analysis are summarized
in table 2. In univariable analysis, at time of diagnosis of NCPH,
no differences between case patients and control subjects were
found in median HIV infection date (December 1989 vs March
1990), median cohort registration date (July 1995 vs December
1995), and median duration of cohort follow-up (11.9 vs 12.0
years), reflecting proper selection of control subjects. Sex and
race did not differ between the 2 groups. Patients with NCPH
were significantly older than their matched control subjects (52
vs 43 years; odds ratio [OR] per 10 years older, 2.9; 95% con-
fidence interval [CI], 1.4–6.1), and HIV was transmitted more
often through homosexual intercourse (OR, 4.5; 95% CI, 1.2–
17). At time of diagnosis, median CD4 cell count was sub-
stantially lower (165 vs 522 cells/mL) and more often !200 cells/
mL (53% vs 4%; ) in individuals with NCPH. NadirPp .001
CD4 cell count was also lower (103 vs 164 cells/mL) but without
statistical significance. Spleen sequestration with lymphopenia
cannot explain the low absolute CD4 cell count in NCPH pa-
tients, because of concomitant lower CD4 cell percentage (19%
vs 27%; ). No differences were found in HIV-1–RNAP ! .001
levels at time of diagnosis, maximum HIV-1–RNA levels, and
clinical Centers for Disease Control and Prevention disease
stage. Alanine aminotransferase levels were more often elevated
above normal value ( ), alkaline phosphatase were morePp .001
often elevated above normal value ( ), and blood plate-P ! .001
lets were more often reduced below normal value ( ) inP ! .006
NCPH patients. Most of the risk factors for nonalcoholic fatty
liver disease [17, 18], including dyslipidemia, high blood pres-
sure (data not shown), central obesity, and lipodystrophy, did
not differ between case patients and control subjects. However,
diabetes mellitus was overrepresented in NCPH patients (27%
vs 4%; ). We attributed a significantly lower body massPp .013
index in the NCPH group to weight loss in the context of
progressive liver disease.
Association of antiretroviral treatment and NCPH.
The antiretroviral treatment history of patients with NCPH and
control subjects is shown in table 3. Individuals with NCPH
started ART more frequently with monotherapy (40% vs 27%)
or dual therapy (33% vs 15%), compared with control subjects,
who initiated more often with combination ART (27% vs 48%).
In univariable analysis, exposure to any ART was significantly
longer in NCPH patients (OR per year exposure, 1.31; 95%
CI, 1.04–1.65). They were significantly longer exposed to NRTI
(OR 1.33; 95% CI, 1.06–1.66), whereas exposure to protease
inhibitors and nonnucleoside reverse-transcriptase inhibitor
did not differ. Because in the published literature an association
between DDI and NCPH is postulated, we analyzed different
NRTI backbones with and without DDI. DDI with stavudine
(OR, 2.06; 95% CI, 1.36–3.13) and DDI with other NRTI (not
zidovudine and not stavudine; OR, 2.13; 95% CI, 1.35–3.37)
showed a significant association with NCPH, whereas the effect
for the combination of DDI and zidovudine was attenuated
(OR, 1.59; 95% CI, 0.88–2.89; ). Backbones withoutPp .13
DDI were conversely associated with the development of NCPH
(OR, 0.82; 95% CI, 0.70–0.96). Among individual antiretroviral
drugs, DDI exposure was clearly standing out in NCPH patients
(OR, 3.44; 95% CI, 1.46–8.14). All case patients had a treatment
history with DDI (100% vs 35%; ). Cumulative ex-P ! .001
posure to ritonavir (therapeutic dose; OR, 1.42; 95% CI, 1.04–
1.94) and to nelfinavir (OR, 1.39; 95% CI, 1.04–1.86) was also
increased in patients with NCPH. In contrast, use of lamivudine
was significantly higher in the control group (OR, 0.67; 95%
CI, 0.49–0.91).
The final bivariable model is presented in table 4. A full
multivariable model was not possible because of the low case
number. After adjustment for the different covariables, only
exposure to DDI remained a highly significant risk factor for
the development of NCPH.
Outcome. Mortality after diagnosis of NCPH differed from
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Table 3. Comparison of Antiretroviral Therapy (ART) History of Patients with Noncirrhotic Portal
Hypertension and Matched Control Subjects at Time of Diagnosis
ART or individual antiretroviral drugs
Cumulative median
years (IQR)
Odds ratio
(95% CI) per
year exposure P a
For case
patients
(n p 15)
For control
subjects
(n p 75)
Any ART 8 (5–11) 6 (3–8) 1.31 (1.04–1.65) .022
Combination ART 6 (3–9) 4 (1–7) 1.17 (0.96–1.43) .13
NRTIs 8 (5–11) 6 (3–8) 1.33 (1.06–1.66) .015
NNRTIs 1 (0–5) 0 (0–3) 1.12 (0.89–1.40) .33
PIs unboosted 3 (1–5) 1 (0–3) 1.18 (0.96–1.46) .12
PIs boosted 0 (0–4) 0 (0–2) 1.19 (0.93–1.52) .16
Didanosine plus stavudine 2 (0–4) 0 (0–0) 2.06 (1.36–3.13) .001
Didanosine plus zidovudine 0 (0–0) 0 (0–0) 1.59 (0.88–2.89) .13
Didanosine plus another (not zidovudine, not stavudine) 1 (0–3) 0 (0–0) 2.13 (1.35–3.37) .001
Backbone without didanosine 4 (1–7) 8 (4–11) 0.82 (0.70–0.96) .015
Zidovudine 1 (0–3) 2 (0–5) 0.91 (0.73–1.12) .36
Zalcitabine 0 (0–0) 0 (0–0) 0.96 (0.50–1.87) .91
Didanosine 5 (4–6) 0 (0–1) 3.44 (1.46–8.14) .005
Stavudine 3 (2–5) 1 (0–3) 1.24 (0.99–1.55) .06
Lamivudine 0 (0–2) 3 (0–6) 0.67 (0.49–0.91) .01
Abacavir 0 (0–1) 0 (0–2) 0.91 (0.67–1.24) .54
Tenofovir 0 (0–1) 0 (0–0) 1.44 (0.88–2.37) .15
Efavirenz 0 (0–5) 0 (0–2) 1.24 (0.96–1.61) .10
Nevirapine 0 (0–0) 0 (0–0) 0.81 (0.39–1.68) .57
Saquinavir 0 (0–1) 0 (0–0) 1.19 (0.77–1.83) .44
Ritonavir (full dose) 1 (0–3) 0 (0–1) 1.42 (1.04–1.94) .029
Indinavir 0 (0–2) 0 (0–1) 0.95 (0.69–1.31) .76
Nelfinavir 0 (0–5) 0 (0–1) 1.39 (1.04–1.86) .028
Lopinavir/r 0 (0–0) 0 (0–0) 0.81 (0.40–1.62) .55
Amprenavir 0 (0–0) 0 (0–0) 2.62 (0.74–9.27) .14
Atazanavir 0 (0–0) 0 (0–0) 0.80 (0.29–2.21) .67
NOTE. For the drugs fosamprenavir, tipranavir, and darunavir, the number of exposed patients was too small for calculations.
CI, confidence interval; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse-
transcriptase inhibitor; PI, protease inhibitor.
a From conditional logistic regression.
that of the matched control subjects. Whereas none of the
control subjects died during the median follow-up of 12 years
(IQR, 8–17 years), 4 patients with NCPH (27%) died of liver
disease during the same follow-up time (median interval, 12
years; IQR, 9–18 years); among these 4 patients, 2 died of
variceal hemorrhage and 2 of liver failure.
DISCUSSION
In this nested case-control study, prolonged exposure to DDI
was the only independent risk factor for NCPH in HIV-infected
patients. Significant associations for NCPH in univariable anal-
ysis such as age, homosexual transmission category, low CD4
cell count, diabetes mellitus, low body mass index, and exposure
to NRTI, ritonavir, and nelfinavir did not remain stable in
bivariable models. This is in agreement with the recently pub-
lished case reports and case series on NCPH in HIV-infected
persons, in which DDI was suspected to play a major role in
the pathogenesis of NCPH (table 1). Some studies have im-
plicated nevirapine as a causative agent [7, 8, 10], but we did
not find any evidence for that.
Idiopathic NCPH is a poorly understood condition attrib-
uted to obstructive portal venopathy [19, 20]. Pathologically,
2 types of lesions have been described: alterations in small
vessels, regarded as the initial lesions, and changes in liver
architecture consisting of fibrosis and/or nodule formation, re-
garded as secondary [21]. Histological findings are very het-
erogeneous and include periportal and perisinusoidal fibrosis,
hepatoportal sclerosis, nodular regenerative hyperplasia, and
incomplete septal cirrhosis [19, 20, 22]. These histological dif-
ferences might reflect chronologic progression of a single dis-
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Table 4. Bivariable Odds Ratios (ORs) for the Effect of Didanosine (DDI) on Noncirrhotic Portal Hypertension
and ORs for the Covariables Before and After Adjustment for DDI
Covariable
Unadjusted
covariable
Covariable
adjusted for DDI
DDI adjusted
for covariable
OR (95% CI) OR (95% CI) P OR (95% CI)a P
Age, per 10 years older 2.57 (1.29–5.13) 3.69 (0.54–25.0) .18 4.93 (1.21–20.1) .026
Homosexual transmission category 4.52 (1.19–17.2) 133.6 (0.13–1.3  105) .17 5.57 (1.24–25.1) .025
CD4 cell count, !200 cells/mL 34.3 (4.25–277) 359.4 (0.04–3.6  106) .21 4.68 (1.01–21.7) .049
Diabetes mellitus 8.78 (1.58–48.7) 1.57 (0.02–108) .83 3.37 (1.40–8.15) .007
Therapy, per year
NRTI (not DDI) 0.80 (0.67–0.97) 1.18 (0.77–1.81) .45 4.79 (1.18–19.5) .029
NNRTI 1.12 (0.89–1.40) 1.44 (0.88–2.37) .15 4.47 (1.26–15.8) .02
Protease inhibitor 1.18 (0.96–1.46) 1.21 (0.72–2.02) .47 3.91 (1.33–11.5) .013
Lamivudine 0.67 (0.49–0.91) 0.81 (0.46–1.42) .46 2.94 (1.29–6.67) .01
Ritonavir 1.42 (1.04–1.94) 1.17 (0.74–1.82) .50 3.37 (1.38–8.22) .008
Nelfinavir 1.39 (1.04–1.86) 1.61 (0.88–2.93) .12 4.23 (1.32–13.5) .015
NOTE. CI, confidence interval; NNRTI nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase
inhibitor.
a The unadjusted OR for DDI was 3.44 (95% CI, 1.46–8.14; ).Pp .005
ease. Vascular alterations result in hepatic venoocclusive disease
and lead to the syndrome of NCPH [19, 23]. In HIV-positive
patients with symptomatic NCPH, the most common histo-
logical finding was nodular regenerative hyperplasia; Schiano
et al [10] described hepatoportal sclerosis, and Maida et al [5,
11] described microvesicular steatosis, unspecific liver fibrosis,
and periportal fibrosis (table 1). Liver biopsies of our NCPH
patients mainly showed periportal fibrosis.
Idiopathic NCPH has been associated with certain drugs and
systemic diseases, including hypercoagulability, autoimmune
disorders, and myeloproliferative or lymphoproliferative dis-
orders [24]. Most of these diseases are known to cause vascular
damage. The pathomechanism of DDI causing NCPH remains
hypothetical. Prolonged DDI exposure might lead to a mito-
chondrial damage [25, 26], injuring endothelial cells. 6-thiogua-
nine, another nucleoside analogue used for the treatment of
leukemia, has been described to cause hepatic venoocclusive
disease resulting in NCPH [27]. In the Data Collection on
Adverse Events for Anti-HIV Drugs (D:A:D study), a signifi-
cant increased risk of myocardial infarction associated with
recent use of DDI was observed [28]. This finding, however,
could not be confirmed in the Strategies for Management of
Antiretroviral Therapy (SMART) study, in which no association
of DDI use was found with either altered risk of cardiovascular
disease or altered levels of inflammatory and coagulation mark-
ers [29].
The pathogenesis of NCPH in HIV infection is probably
multifactorial. Besides ART, a prothrombotic state was postu-
lated to be an important causative factor leading to micro-
thrombosis and vascular obstruction. Several reports have
noted thrombophilic abnormality in affected patients [9, 13,
30]. HIV might predispose to hypercoagulability and small ves-
sel thrombosis [31, 32]. Furthermore, HIV is thought to trigger
HIV-associated pulmonary hypertension by direct endothelial
toxicity [33]. A similar mechanism could occur in the liver.
The patients with NCPH in our study did not have signs or
symptoms of a prothrombotic state, pulmonary hypertension,
or a disturbed endothelial function.
Univariable results of our study showed an association of
age and homosexual transmission category. In a population not
infected with HIV, NCPH with nodular regenerative hyperplasia
seems to be more prevalent in the elderly. An autopsy study
found a 17-fold higher prevalence in patients aged 180 years,
compared with patients aged !60 years [21]. This might reflect
the higher prevalence of systemic diseases such as lymphopro-
liferative and myeloproliferative disorders in an elderly popu-
lation. Systemic diseases were excluded in case patients of our
study. Maida et al [5, 11] reported an overrepresentation of
the homosexual transmission category in NCPH and HIV. In
the case series by Mallet et al [6], sex was equally distributed,
and in the other case series [9, 10, 13], distribution of HIV
transmission was not mentioned. Diabetes mellitus was more
common in our NCPH patients ( in univariable anal-Pp .013
ysis). However, diabetes mellitus is not known to cause NCPH,
either in a general population or in HIV-infected persons.
The strength of this study is its case-control design. To our
knowledge, this is the only case-control study to investigate risk
factors for the development of NCPH. In addition, case patients
met well-defined criteria for the diagnosis of NCPH: endo-
scopically confirmed esophageal varices as a sign of portal hy-
pertension, exclusion of cirrhosis in biopsies, and absence of
known causes for liver disease. Limitations include the relatively
small sample size due to the rarity of symptomatic NCPH.
Therefore, type 1 errors cannot be excluded. We could evaluate
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only information and laboratory values collected within the
protocol of the Swiss HIV Cohort Study. We retrospectively
could not search for coagulopathies as a possible cofactor in
the pathogenesis of NCPH. Case patients were identified by
physicians remembering affected patients. Less severe cases
might have escaped detection. We cannot rule out the possibility
that some of our control subjects had asymptomatic NCPH.
An important finding of this study is that long-term toxicity
of antiretroviral drugs might emerge only after decades. As
persons with HIV infection in industrialized countries live
longer and ART exposure is prolonged, we need to be alert for
novel clinical manifestations attributable to drug-related ad-
verse events.
In summary, we described a case series of 15 HIV infected
patients with NCPH and assessed associated risk factors in a
nested case-control analysis. We found a strong correlation be-
tween the exposure to DDI and the development of NCPH.
Because NCPH may result in dramatic complications with in-
creased mortality, a high index of suspicion is needed in DDI-
exposed patients with clinical signs of liver disease, and rapid
evaluation is warranted. Besides symptomatic treatment of por-
tal hypertension, DDI needs to be withdrawn.
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